Postdoctoral position in Immunology/Infectious diseases
The Laboratory of Experimental Immunology is an energetic group that studies human immunology with a particular interest in the antibody response to HIV, Ebola virus, Sars-CoV-2 and other infectious pathogens. Our goal is to precisely understand the biology of humoral immunity and to use this knowledge to effectively prevent and treat infectious diseases.
To this end, our laboratory works with a wide range of techniques in molecular immunology and facilitates different humanized mouse models. Moreover, we conduct clinical trials that enable us to translate our findings into clinical applications. Our group is dedicated to provide an excellent work environment for pursuing forefront and innovative science, and strongly supports the individual development of all members in our group.
The applicant we are looking for should be highly motivated and excited about science. He/She should be enthusiastic, skilled, and talented to address and solve scientific questions. The applicant should be experienced in the fields of molecular immunology/biology and should be a strong team player. All applicants must hold a Ph.D., M.D. or M.D./Ph.D. degree in cell/molecular biology/immunology or related field and should have demonstrated an outstanding performance through their undergraduate and graduate training. The salary will be based on TV-L.
We are very much looking forward to your application. Please submit your CV, brief statement of your research interest, list of publications and two references to email@example.com or firstname.lastname@example.org.
For further information concerning our research the following publications are recommended:
mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. (2022). Gruell H, Vanshylla K, Tober-Lau P, Hillus D, Schommers P, Lehmann C, Kurth F, Sander LE, Klein F. Nature Medicine.
Analysis of antibodies from HCV elite neutralizers identifies genetic determinants of broad neutralization. (2021). Weber T, Potthoff J, Bizu S, Labuhn M, Dold L, Schoofs T, Horning M, Ercanoglu MS, Kreer C, Gieselmann L, Vanshylla K, Langhans B, Janicki H, Ströh LJ, Knops E, Nierhoff D, Spengler U, Kaiser R, Bjorkman PJ, Krey T, Bankwitz D, Pfeifer N, Pietschmann T, Flyak AI, Klein F. Immunity.
Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients.(2020). Kreer C, Zehner M, Weber T, Ercanoglu MS, Gieselmann L, Rohde C, Halwe S, Korenkov M, Schommers P, Vanshylla K, Di Cristanziano V, Janicki H, Brinker R, Ashurov A, Krähling V, Kupke A, Cohen-Dvashi H, Koch M, Eckert JM, Lederer S, Pfeifer S, Wolf T, Vehreschild MJGT, Wendtner C, Diskin R, Gruell H, Becker S, Klein F.. Cell.
Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody.(2020). Schommers P, Gruell H, Abernathy ME, Tran M-K, Dingens AS, Gristick HB, Barnes CO, Schoofs T, Schlotz M, Vanshylla K, Kreer C, Weiland D, Holtick U, Scheid C, Valter MV, van Gils MJ, Sanders RW, Vehreschild JJ, Cornely OA, Lehmann C, Fätkenheuer G, Seaman MS, Bloom JD, Bjorkman J, Klein F. Cell.
Polyclonal and convergent antibody response to Ebola virus vaccine rVSV-ZEBOV. (2019). Ehrhardt SA, Zehner M, Krähling V, Cohen-Dvashi H, Kreer C, Elad N, Gruell H, Ercanoglu MS, Schommers P, Gieselmann L, Eggeling R, Dahlke C, Wolf T, Pfeifer N, Addo MM, Diskin R, Becker S, Klein F. Nature Medicine.